Baby Vaccine Study (Sched3)

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

November 1, 2017

Study Completion Date

June 30, 2021

Conditions
Infectious Diseases
Interventions
BIOLOGICAL

DTaP/IPV/Hib vaccine

Given at 2, 3 and 4 months to Group 1 and 2

BIOLOGICAL

13 valent Pneumococcal Conjugate Vaccine

Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2

BIOLOGICAL

Rotavirus vaccine

Given at 2 and 3 months to Group 1 and 2

BIOLOGICAL

4-component Meningococcal B vaccine

Given at 2, 4 and 12 months to Group 1 and 2

BIOLOGICAL

Meningococcal C/Hib vaccine (MenC/Hib vaccine)

Given at 12 months to Group1 and 2

BIOLOGICAL

Measles/Mumps/Rubella Vaccine (MMR vaccine)

Given at 13 months to Groups 1 and 2

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Oxford

All Listed Sponsors
collaborator

University College, London

OTHER

collaborator

Public Health England

OTHER_GOV

lead

University of Oxford

OTHER

NCT02482636 - Baby Vaccine Study (Sched3) | Biotech Hunter | Biotech Hunter